Claims

1. Use of niraparib or a salt thereof in the manufacture of a medicament for the treatment of prostate cancer wherein the medicament is to be administered in a safe and effective amount to a human in need thereof and wherein the human is carrying at least one DNA repair anomaly selected from the group consisting of BRCA-1, BRCA-2, FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM..

2. The use of claim 1, wherein the prostate cancer is a castration-resistant prostate cancer or metastatic castration-resistant prostate cancer.

3. The use of claim 2, wherein the prostate cancer is antiandrogen resistant.

4. The use of any one of claims 1-3, wherein the DNA repair anomaly is BRCA-1 or BRCA-2.

5. The use of any one of claims 1-4, wherein the prostate cancer is castration-resistant prostate cancer.

6. The use of any one of claims 1-4, wherein the prostate cancer is metastatic castration-resistant prostate cancer.

7. The use of any one of the preceding claims, wherein niraparib is to be administered in an amount of from 30 mg/day to 400 mg/day.

8. The use of claim 7, wherein the amount of niraparib to be administered is 300 mg/day.

9. The use of claim 8, wherein niraparib is to be administered as once daily oral administration in three 100 mg oral dosage forms.